LIAISON PLEX Gram-Negative Blood Culture Assay Catalog No. 20-005-303
Published November 11, 2026 · Recall initiated: October 5, 2026
Summary
FDA records medical device Class II recall Z-0359-2027, published November 11, 2026 and initiated October 5, 2026. Recalling firm: Luminex Corporation; Status: Ongoing; Reported quantity: 30,168 test cartridges (2,514 Kits); Lot: All lots UDI-DI pending. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Instructions for Use updated to include explicit guidance that repeat testing is recommended whenever a positive family-level only result is obtained. Issue may contribute to incorrect or delayed diagnosis of bloodstream infection.
What to do
Voluntary: Firm initiated
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Luminex Corporation
- Distributor
- US distribution nationwide. No OUS distribution.
- Lot
- All lots UDI-DI pending
- Risk classification
- Class II
- Area (FDA)
- device
- Country
- United States
Related recalls
- FDAHalyard ARTHROSCOPY PACK. Model/Catalog Number: SAMM014-21.November 11, 2026
- FDAintelerad IntelePACS softwareNovember 11, 2026
- FDAVerigene Gram Positive Blood Culture (BC-GP) Nucleic Acid TestAugust 14, 2024
- FDAVERIGENE Enteric Pathogens Nucleic Acid Test, Part No. 30-002-23July 13, 2022
- FDAVerigene Processor SP, Models 10-0000-07/10-0000-07R a component of the Verigene systemMay 25, 2022
- FDAVerigene Processor SP with assay Luminex, VERIGENE Gram-Negative Blood Culture Nucleic Acid Test, BC-GN, IVD -August 19, 2020
Questions about this recall
Was LIAISON PLEX Gram-Negative Blood Culture Assay Catalog No. 20-005-303 recalled?
Yes. FDA published recall Z-0359-2027 on November 11, 2026. Reported hazard: Instructions for Use updated to include explicit guidance that repeat testing is recommended whenever a positive family-level only result is obtained. Issue may contribute to incorrect or delayed diagnosis of bloodstream infection.
What should I do if I have this product?
Voluntary: Firm initiated